ArticleEJNMMI radiopharmacy and chemistry2019
Radionuclides: medicinal products or rather starting materials?
Article in EJNMMI radiopharmacy and chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Review
- To be GMP or not to be- a radionuclide's question.EJNMMI radiopharmacy and chemistry · 2025Article
- Total-body positron emission tomography imaging to accelerate radiotracer discovery pipelines.Pharmacological reviews · 2025Review
- Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation?EJNMMI radiopharmacy and chemistry · 2024Review
- Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework.EJNMMI radiopharmacy and chemistry · 2024Article
- The revision of the pharmaceutical legislation - it is time to act for nuclear medicine in Europe.European journal of nuclear medicine and molecular imaging · 2023Article
- Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?EJNMMI radiopharmacy and chemistry · 2023Review
- Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends.Frontiers in nuclear medicine · 2022Article
- Cold Kit Labeling: The Future ofFrontiers in medicine · 2022Review
- Radiolabeled PSMA Inhibitors.Cancers · 2021Review
- Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.EJNMMI radiopharmacy and chemistry · 2021Review
- Emerging Radionuclides in a Regulatory Framework for Medicinal Products - How Do They Fit?Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EU directive 2001/83 describes the community code for medicinal products for human use including radiopharmaceuticals. In its current definition, also radionuclide precursors, such as fluorine-18, need to hold a marketing authorization before being placed on the market. The potential of novel radiopharmaceuticals for nuclear medicine is, although encouraged by European legislation and its respective guidance documents, therefore hampered by the regulatory framework. An update of EU directive 2001/83 would be beneficial for the development of novel radiopharmaceuticals and a safe advance in nuclear medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.